Quick Answer
Theravance Biopharma, Inc. reported Total Assets of $485.57 million for the year ending 2025.
- Theravance Biopharma, Inc. showed an increase of +37.1% in Total Assets from 2024 to 2025.
- This data is from Theravance Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $26.17 million | Q2 2014: $430.59 million | Q3 2014: $381.71 million | Q1 2015: $324.90 million | Q2 2015: $289.48 million | Q3 2015: $257.51 million | Q1 2016: $293.13 million | Q2 2016: $374.49 million | Q3 2016: $356.29 million | Q1 2017: $588.04 million | Q2 2017: $543.89 million | Q3 2017: $486.16 million | Q1 2018: $480.11 million | Q2 2018: $421.36 million | Q3 2018: $370.96 million | Q1 2019: $531.27 million | Q2 2019: $492.45 million | Q3 2019: $445.34 million | Q1 2020: $605.41 million | Q2 2020: $564.33 million | Q3 2020: $512.19 million | Q1 2021: $375.11 million | Q2 2021: $429.25 million | Q3 2021: $403.11 million | Q1 2022: $355.36 million | Q2 2022: $360.76 million | Q3 2022: $763.50 million | Q1 2023: $538.55 million | Q2 2023: $446.63 million | Q3 2023: $413.59 million | Q1 2024: $371.31 million | Q2 2024: $362.03 million | Q3 2024: $356.11 million | Q1 2025: $343.58 million | Q2 2025: $426.04 million | Q3 2025: $415.46 million.
- Over the full 13 years of available data (2013 to 2025), Theravance Biopharma, Inc.'s Total Assets has grown by 1,828.6%.
- Historical annual values: Fiscal year 2025: $485.57 million | Fiscal year 2024: $354.16 million | Fiscal year 2023: $382.00 million | Fiscal year 2022: $607.40 million | Fiscal year 2021: $374.82 million | Fiscal year 2020: $469.06 million | Fiscal year 2019: $408.83 million | Fiscal year 2018: $560.24 million | Fiscal year 2017: $441.40 million | Fiscal year 2016: $639.25 million | Fiscal year 2015: $300.12 million | Fiscal year 2014: $337.77 million | Fiscal year 2013: $25.18 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: